Todas as matérias desta categoria, das mais recentes às mais antigas.
Neuren Pharmaceuticals (ASX:NEU) received a US Food and Drug Administration Orphan Drug Designation for its compound NNZ-2591 to treat neonatal hypoxic-ischemic encephalopathy.
INOVIQ (ASX:IIQ) has signed a validation and licence option agreement with Sonic Healthcare USA to optimise and validate its EXO-OC ovarian cancer early-detection test.
OncoSil Medical (ASX:OSL) reported a 45.8% year-on-year increase in first-quarter sales revenue following approval from the U.S. Food and Drug Administration for its medical device.
Clinuvel Pharmaceuticals (ASX:CUV) has submitted a marketing authorisation dossier in Europe for NEURACTHEL Instant.
Reece (ASX:REH) delivered first-quarter sales revenue of $2.51 billion, up 4.3% from the same period last year.
ResMed (ASX:RMD) reported first-quarter revenue for fiscal year 2027 grew 6% to US$1.4 billion.
Alcidion Group (ASX:ALC) released a year-to-date trading update showing contracted revenue reached $50 million by late September.
Mesoblast (ASX:MSB) reported a 44% year-on-year increase in first-quarter net revenue from Ryoncil sales, which reached US$28 million for the period.
SciDev (ASX:SDV) has secured three new chemistry supply contracts valued at approximately $8 million across the mining, utilities, and infrastructure sectors.
Oneview Healthcare (ASX:ONE) achieved its strongest quarter for new customer additions after signing six healthcare organisations in the three months to September.
Resonance Health (ASX:RHT) secured $6 million in firm commitments via an oversubscribed share placement.
Arovella Therapeutics (ASX:ALA) has dosed its first patient in the SAPPHIRE phase 1 trial of cell therapy ALA-101.
